Risk factors for bone loss with prostate cancer in Korean men not receiving androgen deprivation therapy

Risk factors for bone loss with prostate cancer in Korean men not receiving androgen deprivation therapy

PURPOSE: Preexisting bone loss in men with prostate cancer is an important issue due to the accelerated bone loss during androgen deprivation therapy (ADT). In addition, a high prostate-specific antigen (PSA) level has been reported to be related to bone metabolism. This study assessed the factors a...

Full description

Bibliographic Details
Main Authors:	Sun-Ouck Kim, Taek Won Kang, Dongdeuk Kwon, Kwangsung Park, Soo Bang Ryu
Format:	Article
Language:	English
Published:	Sociedade Brasileira de Urologia 2009-04-01
Series:	International Brazilian Journal of Urology
Subjects:	prostate neoplasm osteoporosis androgen deprivation therapy prostate specific antigen
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382009000200008

Similar Items

Reporting and ideal testosterone levels in men undergoing androgen deprivation for prostate cancer—time for a rethink?
by: Sonja Cabarkapa, et al.
Published: (2018-03-01)

Association of Androgen Deprivation Therapy with Osteoporotic Fracture in Patients with Prostate Cancer with Low Tumor Burden Using a Retrospective Population-Based Propensity-Score-Matched Cohort
by: Sung Han Kim, et al.
Published: (2023-05-01)

Impact of androgen deprivation therapy on cognitive function in men with prostate cancer
by: Yutaka Yamamoto, et al.
Published: (2024-03-01)

The Influence of Androgen Deprivation Therapy on Prostate Size and Voiding Symptoms in Prostate Cancer Patients in Korea
by: Hoon Choi, et al.
Published: (2016-12-01)

External radiotherapy for prostate cancer with or without androgen deprivation: Geneva, 1991 to 2004
by: R Miralbell, et al.
Published: (2009-09-01)

Risk of ischemic stroke in patients with prostate cancer receiving androgen deprivation therapy in Taiwan
by: Kuang-Ming Liao, et al.
Published: (2019-12-01)

Implementing and Evaluating the Impact of BoneRx: A Healthy Bone Prescription for Men with Prostate Cancer Initiating Androgen Deprivation Therapy
by: Jennifer M. Jones, et al.
Published: (2022-05-01)

No increased risk of psoriasis in patients receiving androgen deprivation therapy for prostate cancer: a 17-year population-based study
by: Liu JM, et al.
Published: (2018-09-01)

Cardiometabolic and Skeletal Risk Factors in Black Men with Prostate Cancer Starting Androgen Deprivation Therapy
by: Orvar Gunnarsson, et al.
Published: (2015-04-01)

Androgen deprivation therapy and the risk of subsequent keratitis
by: Dai-Wei Liu, et al.
Published: (2021-01-01)

A Comprehensive Review of Androgen Deprivation Therapy and Immunotherapy on Prostate Cancer
by: ZHU Hui, et al.
Published: (2019-10-01)

Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues
by: Aditya Bagrodia, et al.
Published: (2009-01-01)

Androgen deprivation therapy and risk of cognitive dysfunction in men with prostate cancer: is there a possible link?
by: Myungsun Shim, et al.
Published: (2022-03-01)

Exercise Adherence in Men with Prostate Cancer Undergoing Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis
by: Kellie Toohey, et al.
Published: (2022-05-01)

Incidence of prostate cancer in transgender women undergoing androgen deprivation therapy: A review
by: Saurabh Tyagi, et al.
Published: (2023-01-01)

PSA-Stratified Performance of [<sup>18</sup>F]DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer Patients under Androgen Deprivation Therapy
by: Sara Harsini, et al.
Published: (2022-09-01)

High prevalence of vertebral fractures at initiation of androgen deprivation therapy for prostate cancer
by: Marsha M. van Oostwaard, et al.
Published: (2023-02-01)

Biomarkers of Response to Neoadjuvant Androgen Deprivation in Localised Prostate Cancer
by: Maree Pechlivanis, et al.
Published: (2021-12-01)

Bone densitometric assessment and management of fracture risk in Indian men of prostate cancer on androgen deprivation therapy: Does practice pattern match the guidelines?
by: Manas R Pradhan, et al.
Published: (2012-01-01)

Survival and mortality of elderly men with localized prostate cancer managed with primary androgen deprivation therapy or by primary observation
by: Heikki Seikkula, et al.
Published: (2020-03-01)

Association between Androgen Deprivation Therapy and Risk of Dementia in Men with Prostate Cancer
by: Jui-Ming Liu, et al.
Published: (2021-07-01)

Efficacy and safety of degarelix in Korean patients with prostate cancer requiring androgen deprivation therapy: Open-label multicenter phase III study
by: Dalsan You, et al.
Published: (2015-03-01)

The impact of androgen deprivation therapy on the lipid profile in patients with prostate carcinoma
by: Niraj Kumar, et al.
Published: (2022-06-01)

Impact of Monthly 120 Mg Denosumab on Bone Metabolism in Bone-metastatic Prostate Cancer Undergoing Androgen Deprivation Therapy
by: Jimpei Miyakawa, et al.
Published: (2017-06-01)

The Impact of Exercise on Improving Body Composition and PSA in High-Risk Prostate Cancer Patients on Androgen-Deprivation Therapy
by: Yu-Ching Lin, et al.
Published: (2022-11-01)

Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer
by: James Fradin, et al.
Published: (2023-04-01)

The slope associated with nadir prostate‐specific antigen is prognostically significant in men with hormone‐sensitive prostate cancer after primary androgen deprivation therapy
by: Zeng Zhenhao, et al.
Published: (2022-09-01)

Multidisciplinary Consensus on the Prevention and Treatment of Osteoporosis and Fragility Fractures in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy
by: Enrique Casado, et al.
Published: (2022-01-01)

Relationship between Androgen Deprivation Therapy and Abdominal Adipose Tissue
by: Federico Greco, et al.
Published: (2022-12-01)

Testosterone therapy in men with prostate cancer: literature review, clinical experience, and recommendations
by: Abraham Morgentaler, et al.
Published: (2015-04-01)

Cancer Therapy–Related Cardiac Dysfunction in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
by: Dong‐Yi Chen, et al.
Published: (2023-10-01)

The Beneficial Effect of a Healthy Dietary Pattern on Androgen Deprivation Therapy-Related Metabolic Abnormalities in Patients with Prostate Cancer: A Meta-Analysis Based on Randomized Controlled Trials and Systematic Review
by: Lili Wang, et al.
Published: (2022-10-01)

Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients
by: Yue Wang, et al.
Published: (2017-01-01)

Impact of neoadjuvant androgen deprivation therapy on magnetic resonance imaging features in prostate cancer before radiotherapy
by: Ulrika Björeland, et al.
Published: (2021-01-01)

Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy
by: Yong Jin Kang, et al.
Published: (2017-11-01)

<i>NRG1</i> Genetic Variant Influences the Efficacy of Androgen-Deprivation Therapy in Men with Prostate Cancer
by: Shu-Pin Huang, et al.
Published: (2021-05-01)

The castration level of testosterone and hormonal resistance of prostate cancer in androgen deprivation therapy
by: I. G. Rusakov, et al.
Published: (2020-12-01)

Effect of Androgen Deprivation Therapy on the Results of PET/CT with 18F-Fluciclovine in Patients with Metastatic Prostate Cancer
by: Tore Bach-Gansmo, et al.
Published: (2022-06-01)

Using Exercise and Nutrition to Alter Fat and Lean Mass in Men with Prostate Cancer Receiving Androgen Deprivation Therapy: A Narrative Review
by: Rebekah L. Wilson, et al.
Published: (2021-05-01)

Influence of Androgen Deprivation Therapy on the Development of Sarcopenia in Patients with Prostate Cancer: A Systematic Review
by: Marta Stelmach-Mardas, et al.
Published: (2024-02-01)